Publicacións en colaboración con investigadores/as de Universidade de São Paulo (180)

2024

  1. AI is a viable alternative to high throughput screening: a 318-target study

    Scientific Reports, Vol. 14, Núm. 1

  2. Author Correction: Diagnosis and management of prolactin-secreting pituitary adenomas: a Pituitary Society international Consensus Statement (Nature Reviews Endocrinology, (2023), 19, 12, (722-740), 10.1038/s41574-023-00886-5)

    Nature Reviews Endocrinology

  3. Bleeding during tooth extraction in patients with chronic kidney disease: A cross-sectional pilot study

    Oral Diseases, Vol. 30, Núm. 4, pp. 2617-2624

  4. Bone pattern changes in post liver transplant patients using bisphosphonates

    Special Care in Dentistry, Vol. 44, Núm. 4, pp. 1273-1279

  5. Correction to: AI is a viable alternative to high throughput screening: a 318-target study (Scientific Reports, (2024), 14, 1, (7526), 10.1038/s41598-024-54655-z)

    Scientific Reports

  6. Higher COVID-19 pneumonia risk associated with anti-IFN-α than with anti-IFN-ω auto-Abs in children

    The Journal of experimental medicine, Vol. 221, Núm. 2

  7. IS THE PHOTOBIOMODULATION THERAPY EFFECTIVE IN CONTROLLING POST-SURGICAL SIDE EFFECTS AFTER THE EXTRACTION OF MANDIBULAR THIRD MOLARS? A SYSTEMATIC REVIEW AND META-ANALYSIS

    Journal of Evidence-Based Dental Practice, Vol. 24, Núm. 2

  8. Mucocutaneous histoplasmosis as the first manifestation of AIDS

    Special Care in Dentistry, Vol. 44, Núm. 4, pp. 1059-1064

  9. Oral lesions of systemic lupus erythematosus: A collaborative Latin American study

    Lupus, Vol. 33, Núm. 8, pp. 864-873

  10. Prevalence of human herpesvirus in plasma and saliva of cirrhotic patients: A pilot study

    Special Care in Dentistry

  11. Pseudomonas aeruginosa Bloodstream Infections Presenting with Septic Shock in Neutropenic Cancer Patients: Impact of Empirical Antibiotic Therapy

    Microorganisms, Vol. 12, Núm. 4

  12. Safety and Immunogenicity of a ChAd155-Vectored Respiratory Syncytial Virus Vaccine in Infants 6-7 Months of age: A Phase 1/2 Randomized Trial

    The Journal of infectious diseases, Vol. 229, Núm. 1, pp. 95-107